Save time, stay current, and earn CE. You can rely on The Rx Consultant to deliver practical easy-reading updates on drugs & therapy for front-line pharmacists and nurses.

CE for this article is no longer valid.
Non Subscriber: Buy This Issue

Alzheimer’s Disease and Dementia

Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for the issue, return to this Introduction page and click the "Take the Test" button. The Introduction page will remain open after you open this issue.
You may need to re-size or close the issue in order to see the Introduction page.

Overview

   Dementia, derived from the Latin root “de mens” (away mind) is not a specific diagnosis, but a syndrome or collection of symptoms. Not long ago, “senile dementia” was considered a natural part of the aging process. The same condition in people younger than 65 was termed "presenile dementia" and considered a rare disorder. Early in the 20th century, a type of presenile dementia was identified as Alzheimer’s disease. In the 1970s, researchers concluded that the most common type of dementia in older patients was the same disorder, and the term Alzheimer’s disease (AD) is now applied to patients of all ages.

   Today, AD is recognized as one of a number of neurological conditions previously lumped together as “dementia”. This issue of The Rx Consultant brings you up to date on the management of the dementias you are most likely to see in practice: AD, vascular dementia, dementia with Lewy Bodies, and frontotemporal dementia. Current recommendations for the use of drugs to treat cognitive symptoms (e.g., Aricept,®, Namenda®) as well as behavioral symptoms (e.g., antipsychotics, antidepressants) are included.

Details

Publication Date: 03/01/2008
Expiration Date: 04/01/2011
CE Credit: 2.0 (0.20 CEU)
Type of Activity: Knowledge-based

This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.

Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.

Authors

Author: R. Ronald Finley, B.S. Pharm., R.Ph. is a Lecturer in the Department of Clinical Pharmacy, UCSF School of Pharmacy, and a Clinical Pharmacist for the UCSF Memory and Aging Center Alzheimer's Research Center in San Francisco, CA.

Disclosure Statement

R. Ronald Finley is a member of the Speaker's Bureau for Forest Pharmaceuticals, Inc., Novartis, and Pfizer, Inc.

Target Audience

This accredited program is targeted to pharmacists and nurses.

Goals & Objectives

At the conclusion of this program, participants will be able to:

    1. Describe the pathophysiology, symptoms and general clinical course for Alzheimer's disease and other more common forms of dementia.
    2. Discuss the mechanism of action of acetylcholinesterase inhibitors and memantine. Summarize their role in treatment including efficacy, common side effects and precautions.
    3. Discuss the pharmacological management of behavioral and psychiatric symptoms associated with dementias (e.g., agitation, anxiety, psychosis and depression).

Accreditation Statements

The Rx Consultant is a publication of Continuing Education Network, Inc.

Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a provider of continuing pharmacy education.

Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.

ACPE Universal Activity Number: 428-0000-08-003-H01-P


Exam & Credit Statement Procedures

Upon successful completion of this program and the post test (70%), 2.0 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and program evaluation.

Editorial and Review Board

Chief Editor and CE Administrator


Terry M. Baker, PharmD

Managing Editor


Tracy Farnen, PharmD

Associate Editors


James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Kaiser Permanente
Oakland, CA

Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA

Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA

Consultant Pharmacist
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA

Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA

Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System

Adjunct Clinical Professor
College of Pharmacy
Touro University
Vallejo, CA

Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Stockton, CA

Visiting Associate Professor and Lecturer
Nursing School
Samuel Merritt University
Oakland, CA

Pamela Mausner, MD

Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Detroit, MI

Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Detroit, MI

Senior Editorial Advisor


Gerard Hatheway, PharmD, PhD

Editorial Advisors


Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD

Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners


Emily K.
Meuleman, RN, C, MS

About the Rx Consultant

The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to educate patients about drugs and manage drug therapy. The reader is responsible for confirming the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.

Technical Specifications

Hardware requirements

Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.

Software requirements

Browser that supports TLS 1.1 + and PDF files.

This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.

Adobe Acrobat Reader is recommended, and is required for some browsers.

Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.

Internet Connectivity

Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)

Contact Us

Exam Processing Inquiries

The Rx Consultant
rxmail@rxconsultant.com
1-800-798-3353

Educational Content Inquiries

The Rx Consultant
editor@rxconsultant.com
1-800-798-3353

CE for this article is no longer valid.
Non Subscriber: Buy This Issue